<DOC>
	<DOCNO>NCT00449488</DOCNO>
	<brief_summary>The primary objective study establish effect single bolus EPO , administer within three hour primary PCI first acute myocardial infarction , leave ventricular function .</brief_summary>
	<brief_title>Clinical Study Examine Effects Erythropoietin Left Ventricular Function After Acute Myocardial Infarction</brief_title>
	<detailed_description>Erythropoetin ( EPO ) commonly know effective treatment anemia . However , several important extra-hematopoeitic effect EPO suggest might beneficial set acute myocardial infarction , reduction apoptosis stimulation neovascularisation . Recent animal study provide consistent evidence reduce infarct size improve leave ventricular function cause EPO administration . However , clinical study EPO non-anemic patient scarce . We perform safety study department effect single bolus EPO patient acute myocardial infarction . Serum EPO level increase 200-fold EPO administration associate hypertension , increase thrombocytes thrombotic event . In conclusion , experimental data clearly show single bolus EPO onset acute myocardial infarction reduce myocardial infarct size , improve leave ventricular function . In safety study , EPO administration patient acute myocardial infarction safe well tolerate . This PROBE ( Prospective , Randomised , Open label study Blinded Endpoint ) design study , wich one group receive one bolus EPO 60.000 IU ) intravenously within 3 hour primary PCI procedure group receive standard therapy . After 6 week leave ventricular ejection fraction evaluate planar radionuclide ventriculography .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Successful primary PCI ( TIMI 2/3 ) first acute myocardial infarction , diagnose : chest pain suggestive acute myocardial infarction symptom onset &lt; 12 hour hospital admission , &lt; 24 hour case ongoing ischemia ECG STT segment elevation &gt; 1 mV 2 lead TIMI flow 0/1 primary PCI diagnostic coronary angiography ; Hemoglobin level &gt; 10.6 mmol/L ; Anticipated additional revascularisation within 4 month ; Cardiogenic shock ; Presence serious medical condition Pregnancy/breast feeding Malignant hypertension End stage renal failure ( creatinin &gt; 220 micromol/l ) Previous treatment rhEPO Blood transfusion &lt; 12 week prior randomisation Polycythemia vera Previous acute myocardial infarction Concomitant inflammatory malignant disease Recent trauma major surgery Unwilling sign inform consent Atrial fibrillation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>erythropoietin</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>PCI</keyword>
	<keyword>leave ventricular function</keyword>
</DOC>